The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| APPLIED GENETIC TECHNOL CORP | COM | 03820J100 | 381 | 1,404,515 | SH | SOLE | 1,404,515 | 0 | 0 | ||
| EIGER BIOPHARMACEUTICALS INC | COM | 28249U105 | 4,224 | 560,990 | SH | SOLE | 560,990 | 0 | 0 | ||
| GLAUKOS CORP | COM | 377322102 | 870 | 16,347 | SH | SOLE | 16,347 | 0 | 0 | ||
| VENUS CONCEPT INC | COM | 92332W105 | 290 | 658,657 | SH | SOLE | 658,657 | 0 | 0 | ||
| DARE BIOSCIENCE INC | COM | 23666P101 | 62 | 62,065 | SH | SOLE | 62,065 | 0 | 0 | ||
| THE REALREAL | COM | 88339P101 | 3,531 | 2,354,080 | SH | SOLE | 2,354,080 | 0 | 0 | ||
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 19,217 | 1,614,911 | SH | SOLE | 1,614,911 | 0 | 0 | ||
| SERA PROGNOSTICS | CLASS A COM | 81749D107 | 3,866 | 2,416,241 | SH | SOLE | 2,416,241 | 0 | 0 | ||